Czech National Bank Has $27.57 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Czech National Bank grew its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 0.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 993,497 shares of the biopharmaceutical company’s stock after acquiring an additional 4,395 shares during the period. Czech National Bank’s holdings in Pfizer were worth $27,570,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of PFE. Norges Bank bought a new position in shares of Pfizer during the fourth quarter valued at $2,129,927,000. Wellington Management Group LLP raised its stake in Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after buying an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after buying an additional 8,473,686 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Pfizer by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock worth $1,972,300,000 after buying an additional 8,298,920 shares during the last quarter. Finally, Ruffer LLP raised its stake in Pfizer by 248.7% during the fourth quarter. Ruffer LLP now owns 5,796,012 shares of the biopharmaceutical company’s stock worth $166,837,000 after buying an additional 4,133,786 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.2 %

Pfizer stock traded up $0.33 during midday trading on Thursday, hitting $27.74. 29,652,673 shares of the stock were exchanged, compared to its average volume of 41,237,707. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $39.24. The stock has a market capitalization of $157.19 billion, a price-to-earnings ratio of -462.26, a price-to-earnings-growth ratio of 1.08 and a beta of 0.70. The business’s 50-day moving average price is $27.63 and its 200-day moving average price is $27.73. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 earnings per share. On average, research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $35.86.

Get Our Latest Research Report on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.